Download - Variance (%)
1 2 3 4 5 6 7 8 9 100
5
10
15
20
25
30
35
40
number of pc
va
ria
nc
e [
%]
Var
ianc
e (%
)
Number of principle component
Supplemental figure 1
-15 -10 -5 0 5 10 15-15
-10
-5
0
5
10
15
K-218CCP-218K-216
PC-#1
CCP-216
K-214
CCP-214
K-215
CCP-215
PC
-#2
Supplemental figure 2A
-15-10-5051015-10
-8
-6
-4
-2
0
2
4
6
8
10
CCP-215
K-215
CCP-214
K-214
CCP-216
PC-#1
K-216
CCP-218
K-218
PC
-#3
Supplemental figure 2B
-15 -10 -5 0 5 10 15-10
-8
-6
-4
-2
0
2
4
6
8
10
K-215
CCP-215
K-218
K-214
CCP-218
K-216
PC-#2
CCP-216
CCP-214
PC
-#3
Supplemental figure 2C
Supplemental figure 3A
Supplemental figure 3B
Supplemental figure 3C
Supplemental figure 3D
Supplemental figure 3E
1 2 3 4 5 6 7 8 9 100
10
20
30
40
50
60
number of pc
va
ria
nc
e [
%]
Number of principle component
Var
ianc
e (%
)
Supplemental figure 4
-50 -40 -30 -20 -10 0 10 20 30 40 50-30
-20
-10
0
10
20
30
Co.II-214Cd.II-214
Co.II-218
Cd.II-218
Pb.II-214
Pb.II-218
K-218
K-214
PC-#1
Cd.II-215
Co.II-215
Pb.II-215
K-215
PC
-#2
Supplemental figure 5A
-50 -40 -30 -20 -10 0 10 20 30 40 50-25
-20
-15
-10
-5
0
5
10
15
20
25
Co.II-214
Cd.II-214
Co.II-218
Cd.II-218
Pb.II-214
Pb.II-218
K-218
K-214
PC-#1
Cd.II-215Co.II-215Pb.II-215
K-215PC
-#3
Supplemental figure 5B
-50 -40 -30 -20 -10 0 10 20 30 40 50-25
-20
-15
-10
-5
0
5
10
15
20
25
Co.II-214
Cd.II-214
Co.II-218
Cd.II-218
Pb.II-214
Pb.II-218
K-218
K-214
PC-#1
Cd.II-215Co.II-215
Pb.II-215
K-215PC
-#3
Supplemental figure 5B
-30 -20 -10 0 10 20 30-25
-20
-15
-10
-5
0
5
10
15
20
25
K-214
Pb.II-214K-215
Cd.II-214
Co.II-214
PC-#2
K-218Cd.II-218
Pb.II-215
Pb.II-218
Co.II-215
Co.II-218
Cd.II-215
PC
-#3
Supplemental figure 5C
-30 -20 -10 0 10 20 30-25
-20
-15
-10
-5
0
5
10
15
20
25
K-214
Pb.II-214K-215
Cd.II-214
Co.II-214
PC-#2
K-218Cd.II-218
Pb.II-215
Pb.II-218
Co.II-215
Co.II-218
Cd.II-215
PC
-#3
Supplemental figure 5C
Supplemental figures (supplemental online material)
Supplemental figure 1: Variance explained by the individual principle components (corresponding to Figure 1).
Supplemental figure 2: Principle component analysis based on only the first two principle components (corresponding to Figure 1). A. PC-#1: principle component no. 1, PC-#2: principle component no. 2; B. PC-#1: principle component no. 1, PC-#3: principle component no. 3; C. PC-#2: principle component no. 2, PC-#3: principle component no. 3.
Supplemental figure 3: Kegg pathway mapping of genes deregulated by incubation of normal human bronchial epithelial cells with a combination of 15 µg/l Cd(II), 25 µg/l Co(II) and 550 µg/l Pb(II). Dark red colour indicates that the respective gene is at least two-fold upregulated in two patients. Light red colour means upregulation in at least three patients. Similarly, dark green indicates an at least two-fold upregulation in two patients, whereas light green colour highlights genes downregulated in at least three patients. A. Glutathione metabolism, B. Pyrimidine metabolism, C. Purine metabolism, D. Biosynthesis of steroids, E. Cytochrome P450 metabolism.
Supplemental figure 4: Variance explained by the individual principle components (corresponding to Figure 3).
Supplemental figure 5: Principle component analysis based on only the first two principle components (corresponding to Figure 3). A. PC-#1: principle component no. 1, PC-#2: principle component no. 2; B. PC-#1: principle component no. 1, PC-#3: principle component no. 3; C. PC-#2: principle component no. 2, PC-#3: principle component no. 3.